Low Programmed Death-Ligand 1-Expressing Subgroup Outcomes of First-Line Immune Checkpoint Inhibitors in Gastric or Esophageal Adenocarcinoma.
J Clin Oncol. 2022 Feb 1;40(4):392-402. doi: 10.1200/JCO.21.01862. Epub 2021 Dec 3.
J Clin Oncol. 2022.
PMID: 34860570
Review.